structure-based drug design

AlmaDyne is an AI-powered drug discovery company whose mission is to unlock undruggable targets by mapping the full conformational landscape of disease-relevant proteins in their native biological environment. It models the full dynamic range of proteins in native membrane or cytoplasmic environments to reveal transient conformations and hidden binding pockets, and validates AI-designed candidates in vitro and in vivo with Columbia and King's College London.

AI protein dynamics modelingconformational landscape mappingin vitro validationin vivo validation

Denovo Sciences builds AI-powered technologies for first-principles, structure-based small-molecule drug discovery. Its proprietary platform selects optimal target conformations, designs molecules de novo inside the binding pocket, and prioritizes drug-like, synthetically accessible candidates. The company reports 6 drug discovery programs, 300+ tested AI-generated molecules, and a 30% average hit rate.

ADMET property evaluationAI-powered drug discoveryde novo molecule generationprotein binding site evaluationsynthetic route predictionvirtual screening

FAKnostics is a biopharmaceutical company developing therapeutics and diagnostics based on its Focal Adhesion Kinase (FAK) platform technology to combat metastatic cancers and fibrosis. Its proprietary hydrocarbon-stapled peptide FN-2012 blocks the FAK FAT domain, and its FAKnosTEST companion diagnostic detects cancer in early stages. The company reports more than 30 years of FAK research leadership and has 3 pre-clinical programs in fibrotic diseases.

computational drug discoverydrug discoveryimmunohistochemical (IHC) diagnosticsin-vitro approachesin vivo studiespharmacology